These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15262297)

  • 21. Prevention and treatment of the metabolic syndrome in the elderly.
    Firdaus M
    J Okla State Med Assoc; 2005 Feb; 98(2):63-6. PubMed ID: 15789643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid screening and cardiovascular health in childhood.
    Daniels SR; Greer FR;
    Pediatrics; 2008 Jul; 122(1):198-208. PubMed ID: 18596007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Nicotinic acid: an unjustly neglected remedy].
    Zák A; Zeman M; Vecka M; Tvrzická E
    Cas Lek Cesk; 2006; 145(11):825-31. PubMed ID: 17168412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
    Rosenson RS
    Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and treatment of metabolic syndrome in adolescents with type 2 diabetes.
    Sanders BH; Lubsch LM; West DS
    Ann Pharmacother; 2006 Sep; 40(9):1517-21. PubMed ID: 16896016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B
    Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.
    Carlson LA
    J Intern Med; 2005 Aug; 258(2):94-114. PubMed ID: 16018787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?
    Grundy SM
    Am J Med; 2007 Sep; 120(9 Suppl 1):S3-8; discussion S9. PubMed ID: 17720359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Who needs to care about small, dense low-density lipoproteins?
    Rizzo M; Berneis K
    Int J Clin Pract; 2007 Nov; 61(11):1949-56. PubMed ID: 17935554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Niacin in the metabolic syndrome: more risk than benefit?
    Ginsberg HN
    Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):300-1. PubMed ID: 16932303
    [No Abstract]   [Full Text] [Related]  

  • 34. 4-Hydroxyisoleucine: a plant-derived treatment for metabolic syndrome.
    Jetté L; Harvey L; Eugeni K; Levens N
    Curr Opin Investig Drugs; 2009 Apr; 10(4):353-8. PubMed ID: 19337956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolic syndrome: prevalence, CHD risk, and treatment.
    Sarti C; Gallagher J
    J Diabetes Complications; 2006; 20(2):121-32. PubMed ID: 16504841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of dyslipidemia in patients with complicated metabolic syndrome.
    Davidson MH
    Am J Cardiol; 2005 Aug; 96(4A):22E-25E. PubMed ID: 16098839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic syndrome: screening, diagnosis, and management.
    Miller EL; Mitchell A
    J Midwifery Womens Health; 2006; 51(3):141-51. PubMed ID: 16647666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B
    Am J Cardiol; 2004 Sep; 94(5):588-94. PubMed ID: 15342288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.